Cancers, Vol. 10, Pages 29: Estrogen and Androgen Blockade for Advanced Prostate Cancer in the Era of Precision Medicine

Cancers, Vol. 10, Pages 29: Estrogen and Androgen Blockade for Advanced Prostate Cancer in the Era of Precision Medicine Cancers doi: 10.3390/cancers10020029 Authors: Tetsuya Fujimura Kenichi Takayama Satoru Takahashi Satoshi Inoue Androgen deprivation therapy (ADT) has been widely prescribed for patients with advanced prostate cancer (PC) to control key signaling pathways via androgen receptor (AR) and AR-collaborative transcriptional factors; however, PC gradually acquires a lethal phenotype and results in castration-resistant PC (CRPC) during ADT. Therefore, new therapeutic strategies are required in clinical practice. In addition, ARs; estrogen receptors (ERs; ERα and ERβ); and estrogen-related receptors (ERRs; ERRα, ERRβ, and ERRγ) have been reported to be involved in the development or regulation of PC. Recent investigations have revealed the role of associated molecules, such as KLF5, FOXO1, PDGFA, VEGF-A, WNT5A, TGFβ1, and micro-RNA 135a of PC, via ERs and ERRs. Selective ER modulators (SERMs) have been developed. Recently, estrogen and androgen blockade (EAB) using a combination of toremifene and ADT has been demonstrated to improve biochemical recurrence rate in treatment-naïve bone metastatic PC. In the future, the suitability of ADT alone or EAB for individuals may be evaluated by making clinical decisions on the basis of information obtained from RT-PCR, gene-panel, or liquid biopsy to create a “personalized medicine” or “precision medi...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research